LOQTORZI
Growthtoripalimab-tpzi
BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
LOQTORZI (toripalimab-tpzi) is programmed death receptor-1-directed antibody interactions [moa]. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOQTORZI (toripalimab-tpzi) is a PD-1 blocking monoclonal antibody approved by the FDA on October 27, 2023. It works by binding to programmed death receptor-1 to enhance anti-tumor immune responses. The drug is indicated for oncology patients, though specific indications require clarification from label review.
Growth
Early-stage growth asset with moderate competitive pressure (30) suggests expanding commercial team opportunities in sales and account management.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LOQTORZI positions you in the high-value oncology/immunotherapy space with focus on commercial execution and key opinion leader management. Early product lifecycle (Growth stage) offers opportunity to shape market positioning and build teams in a competitive but established therapeutic area.
Oncology Account Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.